Scientific intelligence record
Experience 2.0
Somatostatin analog
Octreotide is a synthetic cyclic octapeptide analog of somatostatin with greater metabolic stability and longer action than endogenous somatostatin. It binds predominantly somatostatin receptor subtypes 2 and 5, suppressing growth hormone and several gastroenteropancreatic hormones and secretions; effects therefore vary by receptor expression, disease, route, and formulation. Immediate-release injection, depot injection, and delayed-release oral products have distinct pharmacokinetics and regulatory labeling.
Record status
Traceability partial
Last meaningful update: 9/20/2026
global evidence atlas
This is a deduplicated literature screening registry—not a claim that every mention directly proves efficacy or safety. Machine proposals remain visibly separate from governed human appraisal.
500 matching records · ranked 2026-09-18
Page 1 of 20
Europe PMC · 2026 · PMID 41978437 · DOI 10.4274/jcrpe.galenos.2026.2025-10-21
human-observational
Europe PMC · 2026 · PMID 41924411 · DOI 10.7759/cureus.104460
human-observational
Europe PMC · 2026 · PMID 41940233 · DOI 10.1210/jcemcr/luaf332
human-observational
Europe PMC · 2026 · PMID 41771310 · DOI 10.1016/j.ijpharm.2026.126730
preclinical-animal
Europe PMC · 2026 · PMID 41743220 · DOI 10.3389/fped.2026.1750672
human-observational
Europe PMC · 2026 · PMID 42712757 · DOI 10.3389/fendo.2026.1871977
human-interventional
Europe PMC · 2026 · PMID 41938404 · DOI 10.1097/rc9.0000000000000333
human-observational
Europe PMC · 2026 · PMID 42438807 · DOI 10.1210/jcemcr/luag182
human-observational
Europe PMC · 2026 · PMID 41567251 · DOI 10.5223/pghn.2026.29.1.1
preclinical-animal
Europe PMC · 2026 · PMID 42571548 · DOI 10.7759/cureus.112355
human-observational
Europe PMC · 2026 · PMID 42632511 · DOI 10.1016/j.ejphar.2026.179278
preclinical-animal
Europe PMC · 2026 · Source ID doi:10.20944/preprints202603.1700.v3 · DOI 10.20944/preprints202603.1700.v3
human-observational
Europe PMC · 2026 · PMID 42030411 · DOI 10.1210/clinem/dgag180
human-observational
Europe PMC · 2026 · PMID 41877371 · DOI 10.12659/ajcr.951251
human-observational
Europe PMC · 2026 · PMID 41859045 · DOI 10.3892/br.2026.2127
synthesis
Europe PMC · 2026 · PMID 42285749 · DOI 10.1113/jp290901
preclinical-animal
Europe PMC · 2026 · PMID 42555490 · DOI 10.1967/s002449913003
human-observational
Europe PMC · 2026 · PMID 41836257 · DOI 10.3389/fonc.2026.1766563
preclinical-animal
Europe PMC · 2026 · PMID 42314069 · DOI 10.1210/clinem/dgag241
preclinical-animal
Europe PMC · 2026 · PMID 42676050 · DOI 10.22037/uj.v23i03.8610
preclinical-animal
Europe PMC · 2026 · PMID 41719493 · DOI 10.1200/jco-25-01808
human-interventional
Europe PMC · 2026 · PMID 42394805 · DOI 10.1210/jcemcr/luag063
human-observational
Europe PMC · 2026 · PMID 42178742 · DOI 10.12659/ajcr.952519
human-observational
Europe PMC · 2026 · PMID 42396735 · DOI 10.1515/jpem-2026-0122
human-observational
Europe PMC · 2026 · Source ID doi:10.20944/preprints202605.0649.v1 · DOI 10.20944/preprints202605.0649.v1
preclinical-animal
governance and regulatory context
No new outcome conclusion is inferred from discovery metadata. Named accountable approval is required for governed scientific conclusions.
Absence of a record in this pass is not proof that no authorization exists. Status must remain jurisdiction-, product-, formulation-, and date-specific.
MYCAPSSA octreotide delayed-release capsules are FDA-approved for long-term maintenance treatment in acromegaly patients who responded to and tolerated octreotide or lanreotide, according to current labeling.
FDA Drugs@FDA — MYCAPSSA NDA 208232SANDOSTATIN LAR DEPOT is FDA-approved for long-term maintenance treatment in acromegaly after response and tolerance to subcutaneous octreotide, and for long-term treatment of severe diarrhea and flushing episodes associated with metastatic carcinoid tumors and profuse watery diarrhea associated with VIP-secreting tumors, under current label criteria.
Octreotide evidence · ranking key
A tier describes the evidentiary role and design strength of a source. It is not a popularity score, proof that every conclusion is correct, or a substitute for claim-level review.
Large, well-conducted randomized trials; prespecified major outcomes; rigorous systematic reviews or meta-analyses; and major regulatory assessments.
Smaller randomized trials, strong prospective cohorts, prespecified secondary analyses, and high-quality comparative-effectiveness studies.
Retrospective cohorts, claims-database studies, pharmacovigilance analyses, mechanistic human research, and well-documented case series.
Case reports, conference abstracts, preclinical research, hypothesis-generating analyses, and expert commentary.
APA
World Peptide Foundation. (n.d.). Octreotide — Peptide Scientific Intelligence. World Peptide Foundation. (Updated September 20, 2026.) https://www.worldpeptidefoundation.org/directory/octreotide
AMA / Vancouver
World Peptide Foundation. Octreotide — Peptide Scientific Intelligence. World Peptide Foundation website. Updated September 20, 2026. https://www.worldpeptidefoundation.org/directory/octreotide
Ranked research corpus
500
Categorized publications with transparent machine-proposed ranking; human appraisal pending.
Featured tiered studies
0
Cornerstone publications with study-level interpretation, limitations, and tier disclosure.
Research domains
6
Clinical and scientific questions synthesized independently across the evidence atlas.
Governed reviewed evidence
25
Database records promoted through the governed publication workflow—not the corpus total.
Corpus generated 2026-09-18. Counts remain separately labeled to prevent automated screening from being represented as completed human review.
Human experience · separate evidence stream
Eligible observations remain below the privacy and reliability threshold. WPF will not convert a handful of reports into a percentage, trend, or clinical claim.
Observation is valuable human context. It is not evidence of causation, efficacy, or safety.
Public display gate
n ≥ 20 eligible observations
Exact progress remains private before the threshold.
Intelligence snapshot
A compact view of what is represented, what remains unresolved, and how completely the record can be traced.
Ranked research corpus
500
Categorized screening records; proposed rankings remain pending human appraisal.
Featured tiered studies
0
Cornerstone studies with published study-level interpretation and tier disclosure.
Research domains
6
Independent evidence dossiers covering the major research questions.
Governed reviewed evidence
25
Reviewed database records promoted through the governed publication workflow.
Contradictions
0
Conflicting evidence relationships that remain visible.
Research gaps
1
Questions the current record identifies as unresolved.
Connected media
0
Media records explicitly linked to this scientific record.
What we know
The project separates represented evidence from qualification, contradiction, uncertainty, and what the evidence does not establish.
Reconciled domain conclusions
Octreotide no longer relies on the legacy “no public claim” state. Each research domain publishes a bounded conclusion, confidence level, evidence synthesis, limitations, geographic applicability, regulatory interpretation, and research gaps.
Inspect the reconciled evidence atlasThis score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Results are presented from 2 to 3 trials investigating oral octreotide capsules (OOC) as an alternative to injectable somatostatin receptor ligands (iSRLs) in the treatment of acromegaly.
Scientific context
Existing reviewed chemistry is preserved as scientific context. Chemistry and mechanism information do not establish clinical efficacy or safety.
Chemical identity describes the recorded molecular information. It does not establish biological activity, clinical efficacy, safety, or therapeutic suitability.
Explore further
Move from this peptide record into the project's broader evidence, research, comparison, and methodology systems.
Research
Chronology, unresolved research questions, opportunities, and researcher activity remain descriptive rather than evaluative.
1992 · study · Temporal status not established
Annals of internal medicine
1995 · study · Temporal status not established
The Journal of clinical endocrinology and metabolism
1997 · study · Temporal status not established
International journal of pancreatology : official journal of the International Association of Pancreatology
1999 · study · Temporal status not established
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2000 · study · Temporal status not established
Hepato-gastroenterology
2005 · study · Temporal status not established
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
2006 · study · Temporal status not established
The Journal of clinical endocrinology and metabolism
2008 · study · Temporal status not established
Hepato-gastroenterology
2009 · study · Temporal status not established
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010 · study · Temporal status not established
Journal of the American Society of Nephrology : JASN
2010 · study · Temporal status not established
Clinical journal of the American Society of Nephrology : CJASN
2011 · study · Temporal status not established
Clinical endocrinology
2013 · study · Temporal status not established
The Journal of clinical endocrinology and metabolism
2015 · study · Temporal status not established
Endocrine-related cancer
2015 · study · Temporal status not established
Hepatology (Baltimore, Md.)
2015 · study · Temporal status not established
Journal of pain and symptom management
2015 · study · Temporal status not established
World journal of surgical oncology
2017 · study · Temporal status not established
Neuroendocrinology
2018 · study · Temporal status not established
Journal of paediatrics and child health
2021 · study · Temporal status not established
Pituitary
2022 · study · Temporal status not established
Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation
2024 · study · Temporal status not established
Annals of surgery
2024 · study · Temporal status not established
European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
2024 · study · Temporal status not established
Gastroenterology
2025 · study · Temporal status not established
Clinical pharmacokinetics
2026 · regulatory · Temporal status not established
United States (FDA — MYCAPSSA)
2026 · regulatory · Temporal status not established
United States (FDA — SANDOSTATIN LAR DEPOT)
The represented chronology reflects records currently included in the governed dataset and does not claim to represent the entire scientific literature.
No institutional claim record is currently represented for this peptide.
Evidence is missing or not represented as studied; this is not a conclusion that the intervention does not work.
These are bibliographic author identities derived from represented records. Name strings are not proof of unique real-world researcher identity, and publishing organizations are not treated as institutional affiliations.
3 represented evidence records
Years represented: 2005, 2009, 2017
Publishing organizations appearing in records: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Neuroendocrinology
3 represented evidence records
Years represented: 2005, 2009, 2017
Publishing organizations appearing in records: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Neuroendocrinology
3 represented evidence records
Years represented: 2005, 2009, 2017
Publishing organizations appearing in records: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Neuroendocrinology
2 represented evidence records
Years represented: 2009, 2017
Connections
Connections appear only when they are represented by the project’s underlying records.
institution
institution
institution
institution
institution
institution
institution
institution
institution
institution
institution
institution
Traceability
The experience makes incomplete links visible instead of presenting a false impression of perfect provenance.
Source publication state
A governed source may be verified and approved for publication while its claim-to-evidence link is still incomplete.
Reviewer provenance state
“Human scientist reviewed: no” means that specific source-path attribution is not recorded. It does not silently negate the separate publication-review state.
Domain conclusion → Evidence
Connected
Evidence → Source
Connected
Source → Original record
Connected
Traceability documents how the project connects statements to records. It does not establish that a source is scientifically valid or that a claim is clinically true.
Reconciled for 6 domain conclusions and 0 featured studies.
Detailed study-to-domain mappings and original-source paths appear in the Octreotide evidence-governance section.
Inspect the ranked source recordsObservational archive
Observational archive data is intentionally separated from published scientific evidence.
Observational boundary
Insufficient eligible observations are available for display under the current filters.
Insufficient eligible observations are currently represented to display aggregated findings for this peptide.
Regulatory context
Regulatory status is jurisdiction-specific and time-dependent. It is presented as context, not as a recommendation for use or a substitute for scientific evidence evaluation.
United States (FDA — MYCAPSSA)
Regulator: MYCAPSSA)
As of: 9/9/2026 · Temporal status not established
United States (FDA — SANDOSTATIN LAR DEPOT)
Regulator: SANDOSTATIN LAR DEPOT)
As of: 9/9/2026 · Temporal status not established
Research + media
Only media explicitly linked through the project’s relationship system appears here.
No scientifically connected media is currently represented for this peptide.
Sources + provenance
Generated: 9/24/2026, 3:25:46 AM
5 FDA structured product label record(s) were identified for this compound name in openFDA. Label presence reflects an approved product exists under that name; it is not a claim about the specific formulation, dose, or use being discussed anywhere else on this page.
No machine-proposed evidence-strength grades exist yet for this compound; all screening records are unassigned pending further review.
Tier classifies source design and evidentiary role. Confidence reflects risk of bias, sample size, comparator quality, outcome relevance, follow-up, missing data, directness, replication, reporting quality, and whether conclusions stay within the measured results.
Funding and conflicts are disclosed and considered, but sponsorship never automatically changes a tier. Corrections, retractions, and expressions of concern override the original rating.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Somatostatin analogs are indicated for symptom control in patients with gastroenteropancreatic neuroendocrine tumors (NETs).
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Acromegaly is caused by excessive GH secretion and IGF-I overproduction.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Octreotide is a first-generation somatostatin receptor ligand (SRL) approved for acromegaly treatment.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Somatostatin analogues (SSA) have demonstrated antiproliferative activity in addition to efficacy for carcinoid symptom control in functional neuroendocrine tumors (NET).
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Pharmacological prevention of postoperative pancreatic fistula (POPF) after pancreatectomy is open to debate.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Hepatorenal syndrome (HRS), a serious complication of cirrhosis, is associated with high mortality without treatment.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
There are no proven, effective therapies for polycystic kidney disease (PKD) or polycystic liver disease (PLD).
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
No medical treatment is available for polycystic liver disease, a frequent manifestation of autosomal-dominant polycystic kidney disease (ADPKD).
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Acute kidney injury and early allograft dysfunction are 2 common complications after liver transplant.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Chylothorax is a complex condition and many different pharmacological agents have been tried as treatment.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Treatment of acromegaly with intermittent sc injections of octreotide is associated with an increased incidence of cholelithiasis.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Despite a strong rationale for trials of somatostatin analogs in the treatment of Graves' ophthalmopathy (GO), recent studies have provided conflicting results.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Does octreotide reduce vomiting in cancer-associated bowel obstruction?
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
In this study, octreotide was not found to be of benefit in the treatment of acute pancreatitis.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
The postoperative morbidity following pancreaticoduodenectomy (PD) remains very high.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
To assess the value of octreotide in the control of acute bleeding esophageal varices, in a prospective randomized study.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
The aim of this randomized controlled study was to determine whether octreotide (OCT) or scopolamine butylbromide (SB) was the more effective antisecretive drug controlling gastrointestinal (GI) symptoms due to malignant bowel obstruction (MBO) caused by advanced ovarian cancer.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Treatment with somatostatin analogues is the primary medical treatment of acromegaly.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
The effect of octreotide plus interferon-alpha versus octreotide monotherapy on the primary study end points of time to treatment failure (progression, death, stop of study treatment) and long-term survival was investigated in patients with progressive metastatic neuroendocrine foregut (mainly pancreatic) and midgut tumors.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Somatostatin analogs have been shown to control the growth of well-differentiated metastatic neuroendocrine tumors.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Subcutaneous (SC) octreotide acetate effectively relieves the diarrhea and flushing associated with carcinoid syndrome but requires long-term multiple injections daily.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
To determine the effects of the somatostatin analog, octreotide acetate, in patients with acromegaly.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Gastrointestinal angiodysplasias are vascular anomalies that may result in transfusion-dependent anemia despite endoscopic therapy.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Chylothorax is a rare but life-threatening condition in newborns.
Publishing organizations appearing in records: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Neuroendocrinology
2 represented evidence records
Years represented: 2005, 2009
Publishing organizations appearing in records: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2 represented evidence records
Years represented: 2005, 2009
Publishing organizations appearing in records: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2 represented evidence records
Years represented: 2005, 2009
Publishing organizations appearing in records: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2 represented evidence records
Years represented: 2005, 2017
Publishing organizations appearing in records: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, Neuroendocrinology
1 represented evidence record
Years represented: 1992
Publishing organizations appearing in records: Annals of internal medicine
1 represented evidence record
Years represented: 1995
Publishing organizations appearing in records: The Journal of clinical endocrinology and metabolism
1 represented evidence record
Years represented: 2021
Publishing organizations appearing in records: Pituitary
1 represented evidence record
Years represented: 1992
Publishing organizations appearing in records: Annals of internal medicine